News articles about Neogen (NASDAQ:NEOG) have trended somewhat negative on Saturday, according to AlphaOne Sentiment Analysis. AlphaOne, a unit of Accern, rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neogen earned a daily sentiment score of -0.01 on AlphaOne’s scale. AlphaOne also gave news coverage about the company an impact score of 71 out of 100, meaning that recent news coverage is likely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have impacted AlphaOne Sentiment Analysis’s scoring:
- $0.32 EPS Expected for Neogen Co. (NEOG) This Quarter (americanbankingnews.com)
- Neogen Co. (NEOG) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)
- Insider Selling: Neogen Co. (NEOG) CEO Sells 48,469 Shares of Stock (americanbankingnews.com)
- James L. Herbert Sells 8,107 Shares of Neogen Co. (NEOG) Stock (americanbankingnews.com)
- Global Microbiology Culture Market Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023 (openpr.com)
Shares of Neogen (NASDAQ:NEOG) opened at 61.08 on Friday. Neogen has a 52-week low of $47.97 and a 52-week high of $69.09. The company’s 50-day moving average price is $62.01 and its 200-day moving average price is $63.48. The firm has a market capitalization of $2.33 billion, a P/E ratio of 56.56 and a beta of 1.55.
Neogen (NASDAQ:NEOG) last posted its quarterly earnings data on Tuesday, March 21st. The company reported $0.27 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. The firm had revenue of $88.40 million for the quarter, compared to analysts’ expectations of $89.41 million. Neogen had a net margin of 11.49% and a return on equity of 9.54%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter last year, the company posted $0.22 EPS. On average, equities research analysts expect that Neogen will post $1.14 EPS for the current fiscal year.
Separately, Zacks Investment Research raised Neogen from a “hold” rating to a “buy” rating and set a $73.00 price target on the stock in a research report on Thursday, March 23rd.
In other news, CFO Steven J. Quinlan sold 2,676 shares of the firm’s stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $63.68, for a total transaction of $170,407.68. Following the sale, the chief financial officer now owns 12,779 shares in the company, valued at approximately $813,766.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO James L. Herbert sold 48,469 shares of the firm’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $61.29, for a total transaction of $2,970,665.01. Following the sale, the chief executive officer now owns 912,105 shares in the company, valued at approximately $55,902,915.45. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 80,270 shares of company stock worth $4,937,235. Corporate insiders own 4.70% of the company’s stock.
Neogen Company Profile
Neogen Corporation develops, manufactures and markets a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation.
Receive News & Ratings for Neogen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen Co. and related companies with MarketBeat.com's FREE daily email newsletter.